SUPPLEMENTAL MATERIAL TO OUR PROXY STATEMENT
FOR OUR ANNUAL MEETING TO BE HELD ON JUNE 11, 2019
This Supplement dated June 5, 2019 amends and supplements the Proxy Statement of InVivo Therapeutics Holdings Corp. (the “Company”) dated April 25, 2019 (the “Proxy Statement”), with the following information:
Engagement of Proxy Solicitor
Subsequent to filing the Proxy Statement for our 2019 Annual Meeting of Stockholders to be held on June 11, 2019, the Company engaged Georgeson LLC (“Georgeson”), an independent proxy solicitation firm, to assist in soliciting proxies on our behalf. The Company has agreed to pay Georgeson a fee of up to $15,000, plus costs and expenses, for these services. In addition, we have agreed to indemnify Georgeson and certain related persons against certain liabilities relating to or arising out of Georgeson’s engagement. Other costs of soliciting votes in connection with the Proxy Statement have been, or will be, paid by the Company.
The Company has filed the definitive Proxy Statement with the Securities and Exchange Commission (the “SEC”) and has furnished to its stockholders the Proxy Statement in connection with the solicitation of proxies for its 2019 Annual Meeting of Stockholders. The Company advises its stockholders to read the Proxy Statement relating to the 2019 Annual Meeting, as amended and supplemented by this Supplement, because it contains important information. Stockholders may obtain a free copy of the Proxy Statement and other documents that the Company files with the SEC at the SEC’s website at www.sec.gov.